SS
SGMT icon

SBI Securities’s Sagimet Biosciences SGMT Stock Holding History

SBI Securities’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$904 Buy
117
+33
+39% +$224 ﹤0.01% 2839
2026
Q1 		$439 Buy
84
+60
+250% +$334 ﹤0.01% 2935
2025
Q4 		$142 Sell
24
-12
-33% -$86 ﹤0.01% 3310
2025
Q3 		$247 Buy
36
+26
+260% +$211 ﹤0.01% 3248
2025
Q2 		$76 Sell
10
-112
-92% -$473 ﹤0.01% 3615
2025
Q1 		$398 Buy
122
+83
+213% +$348 ﹤0.01% 2957
2024
Q4 		$176 Buy
+39
New +$198 ﹤0.01% 3284

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

SBI Securities's SGMT Position: Q2 2026 in Review

SBI Securities increased its Sagimet Biosciences (SGMT) stake by 39% in Q2 2026, buying an estimated $224 and bringing the position to 117 shares worth $904. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

SBI Securities first reported a position in SGMT in Q4 2024 and has held it in 7 quarters since. 119 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • SBI Securities held 117 shares of Sagimet Biosciences worth $904 as of Q2 2026.
  • SBI Securities bought 33 Sagimet Biosciences shares in Q2 2026, an estimated $224.
  • Sagimet Biosciences made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2839 holding.
  • SBI Securities first reported a position in Sagimet Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 119 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.